Successful examples include anti-HER2 therapy for HER2/neu overexpressing gastric or breast cancer patients [1,2,3,4,5,6], the use of vemurafenib for BRAF-V600E mutant metastatic melanoma patients [7,8,9], or PARP-inhibitors for BRCA-mutant advanced ovarian [10], metastatic breast [11,12] and metastatic pancreatic adenocarcinoma patients [13,14]. Here, ERBB2 is linked to breast carcinoma.